Akebia Therapeutics, Inc. (50) | Human Resources (13)
Browse by Subcategory
Recent Contracts
-
Form of Officer Retention Letter Agreement
(Filed With SEC on May 9, 2022)
-
Separation Agreement with Dell Faulkingham, dated May 5, 2022
(Filed With SEC on May 9, 2022)
-
Amended and Restated Cash Incentive Plan, effective January 19, 2022
(Filed With SEC on March 1, 2022)
-
Non-Employee Director Compensation Program, effective January
(Filed With SEC on February 25, 2021)
-
Consulting Agreement
(Filed With SEC on November 5, 2020)
-
Form of Employee Agreement (Confidentiality, Non-Competition, Non-Solicitation and Development Agreement) applicable to officers
(Filed With SEC on March 26, 2019)
-
Form of Retention and Separation Agreement for Michel Dahan and Nicole R. Hadas
(Filed With SEC on May 9, 2022)
-
Form of Officer Performance-Based Stock Option Award, under the Company's 2014 Incentive Plan, as amended
(Filed With SEC on November 4, 2021)
-
Form of Officer Performance-Based Restricted Stock Unit Award, under the Company's 2014 Incentive Plan, as amended
(Filed With SEC on November 4, 2021)
-
Form of Officer Cash Bonus Letter Agreement
(Filed With SEC on November 4, 2021)
-
Master Consulting Services Agreement, dated as of June 10, 2019, by and between Akebia Therapeutics, Inc. and Scott A. Canute
(Filed With SEC on August 8, 2019)
-
Form of Officer Restricted Stock Unit Award Agreement under 2014 Incentive Plan
(Filed With SEC on March 26, 2019)
-
Amended and Restated Non-Employee Director Compensation Program, effective January 30, 2019
(Filed With SEC on March 26, 2019)